Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

• Status: Completed
• Trial end date: 2017-05-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Aflibercept; Ranibizumab

Criteria

Key Inclusion Criteria:

• Visual impairment predominantly due to neovascular AMD Active

• Newly diagnosed, untreated, angiographically documented choroidal neovascularization (CNV) lesion

Key Exclusion Criteria:

• Stroke or myocardial infarction less than 3 Months prior to study entry

• Active injection or inflammation of either eye at the time of study entry

• Any type of systemic disease (or received treatment for it), including any medical condition (controlled or uncontrolled) that were to be expected to progress, recur, or change to an extent which could bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk